Q-omics provides the consensus-scored NEURL2 profile across patient tissues and cancer cell-line models. NEURL2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NEURL2 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, NEURL2 protein abundance shows 22,666 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, and GBM as cancer lineages where NEURL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEURL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEURL2 survival associations across molecular data types. NEURL2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEURL2 RNA expression–survival associations across cancer types. High NEURL2 expression shows unfavorable associations in LIHC, UCEC, KICH and PRAD, but favorable associations in READ and UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NEURL2 RNA expression.
This table summarizes NEURL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NEURL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEURL2 shows lower tumor expression in UCEC and BRCA and higher tumor expression in LIHC, COAD, LUAD and KICH. The LIHC box plot shows higher NEURL2 RNA expression in tumor versus normal tissue (log2 FC = +0.753, t-test p < 0.001).
This table shows molecular features associated with NEURL2 in patient tissues and cancer cell lines. In patient samples, NEURL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NEURL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
